XOMA Corp (XOMA) is a biotechnology firm based in Berkeley, California. The company specializes in the discovery, development, and licensing of therapeutic antibodies. XOMA has a keen focus on pioneering antibody technologies and turning those discoveries into potential medications to treat life-threatening or debilitating diseases. This is conducted through in-house innovations and partnering with pharmaceutical companies. The company, founded in 1981, is listed on the NASDAQ and operates under the healthcare sector.
XOMA's belief is rooted in the potential of antibodies as breakthrough therapies that can treat serious illnesses. To this end, the corporation has built a comprehensive portfolio of antibody technologies and innovation that addresses various illnesses such as endocrine disorders, cardiovascular diseases, and oncology. XOMA provides unique antibody design, optimization, and even formulation solutions, building a reputation as a preferred partner in the development of antibody drugs.
The company operates mainly by developing new antibodies and out-licenses their commercial rights to larger pharmaceutical companies. That is how XOMA transitioned from a traditional biotech entity to a company that focuses on royalties generated from out-licensed products. This structure allows XOMA to limit its operational risks and develop a diverse and dynamic portfolio of potential revenue-generating licenses.
XOMA's robust product pipeline includes Gevokizumab, a potent anti-inflammatory drug used to treat several ailments, including acne vulgaris, acute coronary syndromes, and osteoarthritis. IL-2, a drug developed for the treatment of metastatic melanoma and renal cell carcinoma, and XMetA, an insulin receptor-activating antibody for the treatment of type 2 diabetes, are other notable mentions.
The company's successful transition to a royalty aggregator and the notable collaboration with Novartis (world-leading Swiss multinational pharmaceutical company) have helped smooth out fluctuations commonly associated with the sector. Therefore, XOMA's shares have made considerable gains over the past few years, and it is expected to continue on this upward trajectory.
Within the biotech sphere, XOMA Corp has earned a reputation for its innovative and reliable contributions. The company's commitment to better health, underscored by the cutting-edge solutions it offers, illustrates its growth potential and positions it as a formidable player within the biopharmaceutical industry.